Immune Resistance Interrogation Study

Official Title

Immune Resistance Interrogation Study

Summary:

This is a prospective research study which will include patients who have progressed on immunotherapy as their most recent line of therapy. This study aims to characterize whether patients who fail to respond to immunotherapy versus patients who respond initially but after a period of time progress demonstrate different genomic, transcriptomic, epigenetic, immunophenotyping profiles. Patients will have a one-time fresh tumour biopsy. Serial blood samples (total amount of blood drawn may not exceed the lesser of 50 mL or 3 mL/kg in an 8 week period), archival tissue (if available) and one stool sample will be collected.

Trial Description

Primary Outcome:

  • Genomic changes associated with primary or acquired resistance to immunotherapy given alone or in combination in patients with advanced solid tumours
  • Transcriptomic changes associated with primary or acquired resistance to immunotherapy given alone or in combination in patients with advanced solid tumours
  • Immunophenotypic changes associated with primary or acquired resistance to immunotherapy given alone or in combination in patients with advanced solid tumours
  • Epigenetic changes associated with primary or acquired resistance to immunotherapy given alone or in combination in patients with advanced solid tumours
Secondary Outcome:
  • Genomic changes associated with subsequent anticancer therapies in patients with advanced solid tumours who have progressed on immunotherapy
  • Transcriptomic changes associated with subsequent anticancer therapies in patients with advanced solid tumours who have progressed on immunotherapy
  • Immunophenotyping changes associated with subsequent anticancer therapies in patients with advanced solid tumours who have progressed on immunotherapy
  • Epigenetic changes associated with subsequent anticancer therapies in patients with advanced solid tumours who have progressed on immunotherapy

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society